The drugmaker Eli Lilly & Co. said Monday it has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that would expand its pipeline of cancer treatments. New York-based ImClone had previously rejected as too low two…

Read the original here:
Eli Lilly agrees to buy ImClone for over $6B